An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Registration Number
- NCT01333007
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 423
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
- Treating physician's decision to initiate first-line Avastin treatment
Exclusion Criteria
- Participation in a clinical trial evaluating anti-cancer therapies
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival 18 months
- Secondary Outcome Measures
Name Time Method Overall survival 18 months Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire 18 months Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment 18 months Treatment of non-squamous NSCLC in clinical practice 18 months Modality of treatment with Avastin (dose, duration, associated chemotherapy) 18 months Safety: Incidence of adverse events 18 months